Animal models mimicking aminoglycoside-induced renal damage

Sandra Rodríguez Salgueiro1, Lucía González Núñez2

1Electron Microscopy Laboratory, National Center for Scientific Research, Havana, Cuba
2Human Morphophysiology Department, Latinamerican School of Medicine, Havana, Cuba

Article Info

Article Type: Editorial

Article History:
Received: 15 December 2015
Accepted: 1 January 2016
ePublished: 6 January 2016

Keywords:
Animal models
Nephrotoxicity
Aminoglycosides
Kanamycin

Aminoglycoside antibiotics consisting gentamicin, kanamycin, amikacin and other can cause acute kidney injury (1). This is a common problem in intensive care medicine (2). It could be fatal (3) or can progress towards chronic kidney disease in survivors (4). Knowledge of the possible mechanisms involved in aminoglycoside-induced nephrotoxicity is largely due to the use of experimental animals (5). Animal models based on treatments with aminoglycosides have also been used to evaluate possible protective or regenerative strategies (6,7). The development of aminoglycoside-induced toxicity models is a complex task, because these compounds can provoke animal death due to renal toxicity and therefore all the adverse effects associated with chronic administration of the aminoglycoside cannot be ascertained (8).

Rats are usually used in studies of aminoglycoside-induced nephrotoxicity, due to their similarity to human beings in terms of the histological structure of the kidneys (9). The deleterious effect of aminoglycosides on rat renal cortex is currently well characterized (5). Although renal histological structure of mice is similar to the rats, they have been used to a lesser extent (10,11).

Nephrotoxicity models commonly use treatments with high doses of an aminoglycoside over a short period of time to induce acute renal injury (12). The acute models have allowed knowing the changes that aminoglycosides induce in the kidney. Epithelial cells of the proximal tubules are the major site of accumulation of these compounds (13).

Aminoglycosides are excreted unchanged through the kidneys, a fraction of filtered aminoglycoside is reabsorbed by proximal tubular cells and causes its toxic effect (5). Nephrotoxicity due to aminoglycosides has been largely recognized as a tubule-interstitial damage, without significant changes in glomeruli. It should be attributed to an early evaluation of the kidneys, as these studies are performed mainly through acute models, in which glomerular effects are not still evident (14).

More recently, it has been shown that aminoglycosides can also induce glomerular lesions, such as congestion, glomerular hypertrophy or atrophy (6), accumulation of amorphous substance in mesangial matrix (15), decreased glomerular filtration rate and other intra-glomerular alterations (5,16).

Since some patients surviving after acute kidney injury can progress towards chronic kidney disease (4), chronic models of aminoglycoside induced toxicity have also been generated. In these models, the evaluation of the state of the kidney is performed later, during the recovery phase following the acute renal damage (11,17).

In chronic models the tubular damage prevails over glomerular damage. These models mimic the clinical condition in which patients are in the recovery phase of renal morphophysiology after acute kidney injury caused by aminoglycosides (13) and at the same time, allow us to study what happens in the recovery phase. This could
be the most appropriate phase to intervene in survivors of acute kidney injury, since progression towards chronic kidney disease has been observed even several months after the initial injury (18). Gentamicin is the aminoglycoside of choice in most experimental models (19). However, with the use of kanamycin, morphological changes in glomeruli, proximal tubules and interstitium have been described similar to that obtained in studies with gentamicin (11,17). In addition, other glomerular effects of these antibiotics have been described through the use of chronic models of kanamycin nephrotoxicity in rats, in terms of increased mesangial matrix at the expense of increasing the number of mesangial cells and also the presence of glomerular synechiae (17). The presence of synechiae is consistent with the subcapsular accumulation of filtered proteins, leading to the adhesion of the denuded glomerular basement membrane to the Bowman's capsule (20). Both glomerular synechiae and mesangial expansion lead to capillary obstruction and this affects the intensity of glomerular filtration (21). The morphological changes in the renal cortex after acute and chronic models of aminoglycoside nephrotoxicity have been described as patchy, due to the simultaneous occurrence of necrosis and regeneration (22,23). Acute models of gentamicin nephrotoxicity have been used to evaluate many protecting candidates (6,24). Chronic models based on treatments with kanamycin have also been used to evaluate possible protective agents addressed to accelerate the recovery of renal morphophysiology after acute renal injury (11,17).

Conclusion

In conclusion, models of nephrotoxicity in rats and mice are essential to achieve a better understanding of the pathophysiology of aminoglycoside-induced damage and to consider strategies for the protection, repair and regeneration, which could be further extrapolated for their use in the clinic (25,26).

Authors' contribution

All authors wrote the paper equally.

Conflicts of interest

The authors declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.

Funding/Support

None.

References

1. Destache CJ. Aminoglycoside-induced nephrotoxicity—a focus on monitoring: a review of literature. J Pharm Pract. 2014;27:562-6.
2. Evenepoel P. Acute toxic renal failure. Best Pract Res Clin Anaesthesiol. 2004;18:37-52.
3. Paquette F, Bernier-Jean A, Brunette V, Ammann H, Lavergne V, Pichette V, et al. Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study. Nephron. 2015;131:153-60.
4. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1078-94.
5. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33-45.
6. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? Pharmacol Res. 2010;62:179-86.
7. Baradaran A, Rafieian-Kopaei M. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. J Renal Inj Prev. 2013;2:15-21.
8. Bach P. Nephrotoxicity: In Vitro to In Vivo Animals to Man. Springer Sci and Business Media; 2013:765.
9. Nielsen S, Kwon TH, Fenton RA, Praetorius J. Anatomy of the Kidney. In: Taal MW, Marsden PA, Skorecki K, Yu AS, Brenner BM, eds. Brenner and Rector’s The Kidney. 9th ed. Saunders; 2011:2962.
10. Jamshidzadeh A, Heidari R, Mohammadi-Samani S, Azarpira N, Najbi A, Jahani P, et al. A comparison between the nephrotoxic profile of gentamicin and gentamicin nanoparticles in mice. J Biochem Mol Toxicol. 2015;29:57-62.
11. Gonzalez NL, Rodriguez SS, Garcia HD, Matos TM, Santos FE, Plasencia FC, et al. La ficocianina acelera la recuperación del tejido renal dañado por sobredosis de kanamicina en roedores (Spanish). Acta Microscopica. 2012;21:147-54.
12. Singh AP, Muthuraman A, Singh JA, Singh N, Grover K, Dhawan R. Animal models of acute renal failure. Pharmacol Rep. 2012;64:31-44.
13. Mitchell RN, Kumar V, Abbas AK, Fausto N. Compendio de Robbins y Cotran Patología estructural y funcional. 7th ed. España S.A: Elsevier; 2007.
14. Rodriguez-Barbero A, Lopez-Novoa JM, Arevalo M. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp Nephrol. 1997;5:47-54.
15. Avdagić N, Cosović E, Nakas-Ićindić E, Mornjaković Z, Zaciragić A, Hadžović-Dzuvo A. Spirulina platensis protects against renal injury in rats with gentamicin-induced acute tubular necrosis. Bosn J Basic Med Sci. 2008;8:331-6.
16. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. Toxicol Appl Pharmacol. 2007;223:86-98.
17. Rodriguez Salgueiro S, Gonzalez Nunez L, Garcia Del Barco Herrera D, Santos Febles E, Maza Ares D, Millares Lopez R, et al. Role of epidermal growth...
factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats. Iran J Kidney Dis. 2014;8:382-8.
18. Chawla LS. Acute kidney injury leading to chronic kidney disease and long-term outcomes of acute kidney injury: the best opportunity to mitigate acute kidney injury? Contrib Nephrol. 2011;174:182-90.
19. Com E, Boitier E, Marchandeau JP, Brandenburg A, Schroeder S, Hoffmann D, et al. Integrated transcriptomic and proteomic evaluation of gentamicin nephrotoxicity in rats. Toxicol Appl Pharmacol. 2012;258:124-33.
20. Rasch R, Nyegaard JR, Marcussen N, Meyer TW. Renal structural abnormalities following recovery from acute puromycin nephrosis. Kidney Int. 2002;62:496-506.
21. Fogo AB. Can glomerulosclerosis be reversed? Nat Clin Pract Nephrol. 2006;2:290-1.

22. Cohen A. Renal Anatomy and Basic Concepts and Methods in Renal Pathology. In: Fundamentals of Renal Pathology. New York: Springer Science Business Media LLC; 2006.
23. Karakoyun B, Yüksel M, Turan P, Arbak S, Alican I. Halofuginone has a beneficial effect on gentamicin-induced acute nephrotoxicity in rats. Rev Drug Chem Toxicol. 2009;32:312-8.
24. Ali BH, Al Za’abi M, Blunden G, Nemmar A. Experimental gentamicin nephrotoxicity and agents that modify it: a mini-review of recent research. Basic Clin Pharmacol Toxicol. 2011;109:225-32.
25. Tamadon MR, Zahmatkesh M, Mousavi S. Administration of antioxidants in chronic kidney disease. J Nephropharmacol. 2015;4:9-11.
26. Nazar C, Bashir F, Izhar S, Anderson J. Overview of management of acute renal failure and its evaluation; a case analysis. J Nephropharmacol. 2015; 4:17–22.

Copyright © 2016 The Author(s); Published by Society of Diabetic Nephropathy Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.